The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.
Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures," said Kevin McCulloch, President and COO of Xeris. "American Regent is the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback